PATENT ABSTRACTS

wherein in one embodiment a collagen-based material including a collagen selected from the group consisting of types I, II and III collagens is freeze dried to form a collagen-based sponge which is contacted with a crosslinking agent selected from the group consisting of a car- bodiimide or a succinimidyl active ester to form an intermediate collagen-based matrix which is subsequently subjected to conditions of severe dehydration to form the collagen-based matrix in sponge or sheet form. In another embodiment. a collagen-based sponge or sheet is first sub- jeeted to conditions of severe dehydration fol- lowed by contacting the thus formed intermediate collagen-based matrix with a car- bodiimide crosslinking compound to form the collagen-based matrix in sponge or sheet form. In still another embodiment of the present inven- tion the cross-linking agent is admixed with the collagen-based material prior to formation of the collagen-based sponge or sheet followed by processing steps of severe dehydration. In a paticularly preferred form of the invention, a carrier compound is incorporated during pro- cessing to form a collagen-based matrix in sponge or sheet form impregnated with a carrier compound wherein the carrier compound is selected from the group consisting of types IV and V collagen, fibronecting, laminin, hyaluronate, proteoglycan, epidermal growth factor, platelet derived growth factor, angiogenesis factor, antibiotic, antifungal agent, spermacidal agent, enzyme and enzyme in- hibitor,

8504422

A N T I B O D I E S , M A N U F A C T U R E A N D U S E

Colin Henry SELF, 76 Lynwood Road, Ealing, London W5 1JG. United Kingdom assigned to CAMBRIDGE PATENT DEVELOPMENTS LTD;

Monoclonal antibodies which are secondary monoclonal antibodies against a complex of a small molecule and a binding protein against the small molecule but which secondary monoclonal antibodies are not antibodies against either the small molecule or against the binding protein. The use of such secondary monoclonal anti- bodies in diagnostic systems and kits are also described.

8504578

S T E R O I D A L L I P O S O M E S

Andrew W JANOFF, Mircea C POPESCU,

185

Alan L WE1NER. Lois E BOLCSAK, Paul A TREMBLAY assigned to THE LIPOSOME COMPANY INC;

Methods and compositions for the preparation of lipid vesicles, the bilayers of which comprise a salt form of an organic acid derivative ofa sterol such as the tris-salt form of a sterol hemi- succinate. The method is rapid, efficient, and does not require the use of organic solvents. The sterol bemisuccinate vesicles may be used to en- trap compounds which are insoluble in aqueous solutions. Such preparations are especially use- ful for entrapping bioactive agents of limited solubility thus enabling administration in vivo.

8504584

M E T H O D O F I N H I B I T I N G A N D I N D U C I N G H U M A N P L A T E L E T

A G G R E G A T I O N

Jack J HAWIGER, Sheila TIMMONS, Thomas J LUKAS, Marek KLOCZEWIAK assigned to NEW ENGLAND DEACONESS HOSPITAL

A method of inhibiting thrombin or ADP- induced human platelet aggregation by fibrinogen has been developed. The administra- tion of the small molecular weight peptide or the synthetic inhibitory molecule of the invention significantly inhibits thrombin or ADP- modified human platelets binding of fibrinogen, a plasma protein necessary for platelet aggrega- tion. The method of the invention is useful for inhibiting of the formation ofhemostatic platelet plugs and of the initiation of thrombotic lesions. The blockage caused by hemostatic plate]et plugs and the damage caused by thrombotic le- sions are major factors in heart disease and stroke. The invention also includes a method of inducing the formation of thrombin or ADP- modified platelet aggregates by administration of a synthetic aggregating molecule which represents a functional substitute for fibrinogen.

8504585

M E T H O D O F I N H I B I T I N G B I N D I N G O F V O N W I L L E B R A N D

F A C T O R T O H U M A N P L A T E L E T S A N D I N D U C I N G I N T E R A C T I O N

O F P L A T E L E T W I T H V E S S E L W A L L S

Jack J HAWIGER, Sheila TIMMONS, Marek KLOCZEWIAK assigned to NEW ENGLAND DEACONESS HOSPITAL